The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Wed., Jun. 29, 8:09 AM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #30. Aastrom Biosciences, Inc. Sanofi's Cell Therapy and Regenerative Medicine Business

Acquirer: Aastrom Biosciences, Inc. (ASTM)
Acquiree: Sanofi's Cell Therapy and Regenerative Medicine Business
Details: Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks.

Vericel is a clinical-stage biotechnology company focused on developing cell therapies that repair and regenerate damaged tissue for use in the treatment of severe, chronic ischemic cardiovascular diseases. Co.'s principal product, ixmyelocel-T is in a clinical development program for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy, critical limb ischemia and craniofacial reconstruction, as well as preclinical research and development programs for the treatment of cardiovascular diseases.

Open the ASTM Page at The Online Investor »

Company Name: 
Vericel Corp

Open the ASTM Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree ASTM Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 30 of 100 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.